Drug intelligence / Profile preview

TEE-MPS2

Development stage: Preclinical
Lead developer: Apteeus
Modality: Small Molecules

Overview

TEE-MPS2 is a preclinical-stage drug candidate being developed by Apteeus for the treatment of Mucopolysaccharidosis type 2 (MPS II), also known as Hunter syndrome. The candidate was identified through Apteeus's proprietary TEEp (Therapeutic Evidence Enhancement) platform, which utilizes high-throughput screening of libraries containing thousands of existing, approved drugs to identify potential new therapeutic applications for rare genetic disorders. MPS II is a rare, X-linked lysosomal storage disease characterized by a deficiency of the enzyme iduronate-2-sulfatase, which leads to the toxic accumulation of glycosaminoglycans in various tissues and organs. TEE-MPS2 represents a drug repositioning strategy intended to provide a novel treatment option for this progressive and multi-systemic condition.

Other names: MPS2MPS-2MPS 2

Beyond the preview

Go deeper on TEE-MPS2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEE-MPS2.

Explore the full profile